Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin

Journal of Immunology

Volumn 176, Issue 8, 2006, Pages 4902-4913

  Adamsson, Jenni ^a   Lindblad, Marianne ^a   Lundqvist, Annika ^a   Kelly, Denise ^b   Holmgren, Jan ^a   Harandi, Ali M ^a,c  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b ROWETT RESEARCH INSTITUTE   (United Kingdom)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHOLERA TOXIN B SUBUNIT; CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE CHOLERA TOXIN B SUBUNIT; CYTOKINE; GANGLIOSIDE GM1; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; MYELOID DIFFERENTIATION FACTOR 88; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; TETANUS TOXOID; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ACIDIFICATION; ADOLESCENT; ANIMAL CELL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; CPG ISLAND; CROSS REACTION; CROSS SPECIES ACTIVITY; CYTOKINE RELEASE; DRUG MECHANISM; ENDOSOME; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SPLEEN CELL; STRUCTURE ACTIVITY RELATION; TH1 CELL;

EID: 33645790032     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.8.4902     Document Type: Article

References (30)

1. Weiner, G. J. 2000. The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J. Leukocyte Biol. 68: 455-463.
2. Krieg, A. M. 2002. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
3. Harandi, A. M., and J. Holmgren. 2004. CpG DNA as potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections. Curr. Opin. Invest. Drugs 5: 141-145.
4. Pisetsky, D. S., and C. Reich. 1993. Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides. Mol. Biol. Rep. 18: 217-221.
5. Hacker, G., V. Redecke, and H. Hacker. 2002. Activation of the immune system by bacterial CpG-DNA. Immunology 105: 245-251.
6. Klinman, D. M., A. K. Yi, S. L. Beaucage, J. Conover, and A. M. Krieg. 1996. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA 93: 2879-2883.
7. Hartmann, G., and A. M. Krieg. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164: 1617-1624.
8. Fearon, K., J. D. Marshall, C. Abbate, S. Subramanian, P. Yee, J. Gregorio, G. Teshima, G. Ott, S. Tuck, G. Van Nest, and R. L. Coffman. 2003. A minimal human immunostimulatory CpG motif that potently induces IFN- and IFN- production. Eur. J. Immunol. 33: 2114-2122.
9. McCluskie, M. J., R. D. Weeratna, and H. L. Davis. 2000. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol. Med. 6: 867-877.
10. Berry, L. J., D. K. Hickey, K. A. Skelding, S. Bao, A. M. Rendina, P. M. Hansbro, C. M. Gockel, and K. W. Beagley. 2004. Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect. Immun. 72: 1019-1028.
11. McCluskie, M., and H. L. Davis. 1998. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161: 4463-4466.
12. Holmgren, J. 1981. Actions of cholera toxin and the prevention and treatment of cholera. Nature 292: 413-417.
13. de Haan, L., and T. R. Hirst. 2004. Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms. Mol. Membrane Biol. 21: 77-92.
14. Holmgren, J., A. M. Harandi, and C. Czerkinsky. 2003. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Expert Rev. Vaccines 2: 205-217.
15. Back, E., A. M. Svennerholm, J. Holmgren, and R. Mollby. 1979. Evaluation of a gangliossde immunosorbent assay for detection of Escherichia coli heat-labile enterotoxin. J. Clin. Microbiol. 10: 791-795.
16. Schnare, M., A. C. Holt, K. Takeda, S. Akira, and R. Medzhitov. 2000. Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr. Biol. 10: 1139-1142.
17. Hemmi, H., O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira. 2000. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745.
18. Manzel, L., L. Strekowsk, P. M. Ismail, J. C. Smith, and D. E. Macfarlane. 1999. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by 4-aminoquinolines and other weak bases: mechanistic studies. J. Pharmacol. Exp. Ther. 291: 1337-1347.
19. Macfarlane, D. E., and L. Manzel. 1998. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160: 1122-1131.
20. Ishii, K. J., F. Takeshita, I. Gursel, M. Gursel, J. Conover, A. Nussenzweig, and D. M. Klinman. 2002. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J. Exp. Med. 196: 269-274.
21. Yamada, H., I. Gursel, F. Takeshita, J. Conover, K. J. Ishii, M. Gursel, S. Takeshita, and D. M. Klinman. 2002. Effect of suppressive DNA on CpG-induced immune activation. J. Immunol. 169: 5590-5594.
22. Hartmann, G., R. Weeratna, Z. Ballas, P. Payette, S. Blackwell, I. Suparto, W. Rasmussen, M. Waldschmidt, D. Sajuthi, R. Purcell, et al. 2000. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol. 164: 1617-1624.
23. Yasuda, K., P. Yu, C. J. Kirschning, B. Schlatter, F. Schmitz, A. Heit, S. Bauer, H. Hochrein, and H. Wagner. 2005. Endosomal translocation of vertebrate DNA activates dendritic cells via TLR9-dependent and -independent pathways. J. Immunol. 164: 1617-1624.
24. Leifer, C. A., M. N. Kennedy, A. Mazzoni, C. Lee, M. J. Kruhlak, and D. M. Segal. 2004. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J. Immunol. 173: 1179-1183.
25. Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5: 190-198.
26. Honda, K., Y. Ohba, H. Yanai, H. Negishi, T. Mizutani, A. Takaoka, C. Taya, and T. Taniguchi. 2005. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434: 1035-1040.
27. Wu, C. C., J. Lee, E. Raz, M. Corr, and D. A. Carson. 2004. Necessity of oligonucleotide aggregation for Toll-like receptor 9 activation. J. Biol Chem. 279: 33071-33078.
28. Maurer, T., A. Heit, H. Hochrein, F. Ampenberger, M. O'Keeffe, S. Bauer, G. B. Lipford, R. M. Vabulas, and H. Wagner. 2002. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32: 2356-2364.
29. Heit, A., F. Schmitz, M. O'Keeffe, C. Staib, D. H. Busch, H. Wagner, and K. M. Huster. 2005. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J. Immunol. 174: 4373-4380.
30. Shirota, H., K. Sano, N. Hirasawa, T. Terui, K. Ohuchi, T. Hattori, K. Shirato, and G. Tamura. 2001. Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells. J. Immunol. 167: 66-74.